ATE435303T1 - Verfahren und zusammensetzungen in verbindung mit gen-silencing - Google Patents
Verfahren und zusammensetzungen in verbindung mit gen-silencingInfo
- Publication number
- ATE435303T1 ATE435303T1 AT03784781T AT03784781T ATE435303T1 AT E435303 T1 ATE435303 T1 AT E435303T1 AT 03784781 T AT03784781 T AT 03784781T AT 03784781 T AT03784781 T AT 03784781T AT E435303 T1 ATE435303 T1 AT E435303T1
- Authority
- AT
- Austria
- Prior art keywords
- stranded rna
- double
- fragments
- gene silencing
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26003—Ribonuclease III (3.1.26.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Silicon Polymers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40276902P | 2002-08-12 | 2002-08-12 | |
US40754302P | 2002-08-30 | 2002-08-30 | |
US46754103P | 2003-05-02 | 2003-05-02 | |
PCT/US2003/022540 WO2004015062A2 (en) | 2002-08-12 | 2003-07-18 | Methods and compositions relating to gene silencing |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE435303T1 true ATE435303T1 (de) | 2009-07-15 |
Family
ID=31721504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03784781T ATE435303T1 (de) | 2002-08-12 | 2003-07-18 | Verfahren und zusammensetzungen in verbindung mit gen-silencing |
Country Status (8)
Country | Link |
---|---|
US (2) | US7700758B2 (de) |
EP (1) | EP1552018B1 (de) |
JP (1) | JP4339852B2 (de) |
CN (1) | CN1685063B (de) |
AT (1) | ATE435303T1 (de) |
AU (1) | AU2003256615A1 (de) |
DE (1) | DE60328214D1 (de) |
WO (1) | WO2004015062A2 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2213737B1 (de) | 2002-02-01 | 2012-11-07 | Life Technologies Corporation | Doppelsträngige Oligonukleotide |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
CA2486658C (en) * | 2002-05-31 | 2014-07-29 | The Regents Of The University Of California | Method for efficient rna interference in mammalian cells |
US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
US20050059019A1 (en) * | 2003-09-11 | 2005-03-17 | Sven Bulow | Gene-related RNAi transfection method |
WO2005026322A2 (en) * | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
EP1706511A4 (de) * | 2004-01-23 | 2010-04-07 | New England Biolabs Inc | Zusammensetzungen und verfahren zur erzeugung kurzer doppelsträngiger rna unter verwendung von mutierter rnase iii |
WO2005095647A1 (ja) * | 2004-03-31 | 2005-10-13 | Takara Bio Inc. | siRNAのスクリーニング方法 |
BRPI0510996A (pt) * | 2004-05-19 | 2007-12-04 | Wyeth Corp | métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico |
WO2006000410A2 (en) * | 2004-06-23 | 2006-01-05 | Bayer Bioscience N.V. | Method for identifying nucleic capable of modulating a gene in a biological system |
US20090124993A1 (en) | 2005-02-17 | 2009-05-14 | Burkly Linda C | Treating neurological disorders |
CN102989012B (zh) | 2005-03-31 | 2015-05-13 | 通用医疗公司 | 监测和调制hgf/hgfr活性 |
CN103638522A (zh) | 2006-01-18 | 2014-03-19 | 通用医疗公司 | 增强淋巴功能的方法 |
CN101494978A (zh) | 2006-05-25 | 2009-07-29 | 比奥根艾迪克Ma公司 | 治疗中风的方法 |
SI2056845T1 (en) | 2006-08-08 | 2018-02-28 | Rheinische Friedrich-Wilhelms-Universitaet Bonn | STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES |
BRPI0721236A2 (pt) * | 2007-01-29 | 2015-09-08 | Wyeth Corp | complexo purificado; célula hospedeira recombinante; método para identificar um composto teste que aumenta a formação de um complexo que inclui o composto teste; método de aumentar a formação de um complexo que inclui um ligante de imunofilina; método de diminuir a atividade do canal de cálcio da abertura dependente da tensão da membrana, e/ou atividade fkbp52, em uma célula; método de estimular o crescimento de neurite e/ou sobrevivência de uma célula neuronal; método de tratar um distúbio associado com disfunção de canal de cálcio tipo l; método de estimular o crescimento de neurite de uma célula neuronal; uso de um ligante de imunofilina; uso de um ligante de imunofilina em combinação com um antagonista do canal de cálcio tipo l; ligante de imunofilina; e composição. |
EP2137655B1 (de) | 2007-04-16 | 2012-07-11 | Momenta Pharmaceuticals, Inc. | Definierte glycoproteinprodukte und entsprechende verfahren |
WO2009070465A1 (en) * | 2007-11-29 | 2009-06-04 | New England Biolabs, Inc. | Selective purification of small rnas from mixtures |
EP2297323A1 (de) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon |
EP2982695B1 (de) | 2008-07-09 | 2019-04-03 | Biogen MA Inc. | Zusammensetzungen mit antikörpern gegen lingo oder fragmenten davon |
AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
WO2013028817A1 (en) | 2011-08-23 | 2013-02-28 | Foundation Medicine , Inc. | Novel kif5b-ret fusion molecules and uses thereof |
KR102142161B1 (ko) | 2012-05-14 | 2020-08-06 | 바이오젠 엠에이 인코포레이티드 | 운동 뉴런 관련 병태 치료용 lingo-2 길항제 |
AU2013296237B2 (en) | 2012-08-03 | 2019-05-16 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
US20150238602A1 (en) | 2012-10-09 | 2015-08-27 | Biogen Idec Ma Inc. | Combination therapies and uses for treatment of demyelinating disorders |
AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
EP2945652B1 (de) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Verfahren zur behandlung cholangiokarzinom |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
EP2971161B1 (de) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Nukleinsäurereinigung |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
US20160051673A1 (en) | 2013-03-29 | 2016-02-25 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
SI3019619T1 (sl) | 2013-07-11 | 2021-12-31 | Modernatx, Inc. | Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe |
AU2014290044B2 (en) | 2013-07-17 | 2020-10-29 | Foundation Medicine, Inc. | Methods of treating urothelial carcinomas |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
EP3169335B8 (de) | 2014-07-16 | 2019-10-09 | ModernaTX, Inc. | Kreisförmige polynukleotide |
JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
EP3349773A4 (de) | 2015-09-14 | 2019-05-01 | Cincinnati Children's Hospital Medical Center | Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
WO2017151517A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
JP7149257B2 (ja) | 2016-07-13 | 2022-10-06 | バイオジェン・エムエイ・インコーポレイテッド | Lingo-1アンタゴニストの投与計画及び脱髄障害の処置のための使用 |
US20210261897A1 (en) * | 2018-06-28 | 2021-08-26 | Curevac Ag | Bioreactor for rna in vitro transcription |
WO2020058759A1 (en) | 2018-09-17 | 2020-03-26 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
CN111073885A (zh) * | 2019-12-31 | 2020-04-28 | 江苏耀海生物制药有限公司 | 一种应用于双链dna片段的纯化方法 |
CN112626152A (zh) * | 2020-12-18 | 2021-04-09 | 深圳大学 | siRNA的制备方法 |
CN113621686A (zh) * | 2021-08-11 | 2021-11-09 | 海南微氪生物科技股份有限公司 | 一种适用于多种病原微生物的检测方法 |
WO2024045192A1 (en) * | 2022-09-02 | 2024-03-07 | Xiaomo Biotech Limited | Inclusion body mediated method for double-stranded rna producing |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
EP1147204A1 (de) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
KR20020097198A (ko) | 2000-03-17 | 2002-12-31 | 베니텍 오스트레일리아 리미티드 | 유전자 사일런싱 |
DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
AU2002258477A1 (en) | 2001-03-08 | 2002-09-24 | Advanced Cell Technology, Inc. | Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture |
US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
CA2486658C (en) * | 2002-05-31 | 2014-07-29 | The Regents Of The University Of California | Method for efficient rna interference in mammalian cells |
-
2003
- 2003-07-18 JP JP2005506133A patent/JP4339852B2/ja not_active Expired - Fee Related
- 2003-07-18 AT AT03784781T patent/ATE435303T1/de not_active IP Right Cessation
- 2003-07-18 DE DE60328214T patent/DE60328214D1/de not_active Expired - Lifetime
- 2003-07-18 AU AU2003256615A patent/AU2003256615A1/en not_active Abandoned
- 2003-07-18 US US10/622,240 patent/US7700758B2/en not_active Expired - Fee Related
- 2003-07-18 CN CN038234416A patent/CN1685063B/zh not_active Expired - Fee Related
- 2003-07-18 EP EP03784781A patent/EP1552018B1/de not_active Expired - Lifetime
- 2003-07-18 WO PCT/US2003/022540 patent/WO2004015062A2/en active Application Filing
-
2008
- 2008-02-11 US US12/028,888 patent/US20080206835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1552018A4 (de) | 2007-11-21 |
EP1552018A2 (de) | 2005-07-13 |
AU2003256615A8 (en) | 2004-02-25 |
WO2004015062A3 (en) | 2005-02-24 |
DE60328214D1 (de) | 2009-08-13 |
WO2004015062A2 (en) | 2004-02-19 |
CN1685063A (zh) | 2005-10-19 |
US20080206835A1 (en) | 2008-08-28 |
CN1685063B (zh) | 2011-12-21 |
US20040038278A1 (en) | 2004-02-26 |
JP4339852B2 (ja) | 2009-10-07 |
AU2003256615A1 (en) | 2004-02-25 |
EP1552018B1 (de) | 2009-07-01 |
JP2005535356A (ja) | 2005-11-24 |
US7700758B2 (en) | 2010-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE435303T1 (de) | Verfahren und zusammensetzungen in verbindung mit gen-silencing | |
Van Dijk et al. | Library preparation methods for next-generation sequencing: tone down the bias | |
Bernt et al. | Genetic aspects of mitochondrial genome evolution | |
DE60324188D1 (de) | Verfahren zur verwendung von riboprimern zur strangverdrängungsreplikation von zielsequenzen | |
ATE469983T1 (de) | Rolling-circle rna-amplifikation | |
WO2004058940A3 (en) | Sirna-mediated gene silencing | |
ATE542918T1 (de) | Verfahren zur quantifizierung von mikro-rnas und kleinen interferenz-rnas | |
ATE483032T1 (de) | Verfahren zur herstellung von oligonukleotiden | |
AR039717A1 (es) | Construcciones de arn de intrones cadena doble y usos de las mismas | |
DE60331321D1 (de) | Verfahren zur wirksamen rna-interferenz in säugerzellen | |
Li et al. | Identification and characterization of microRNAs in the spleen of common carp immune organ | |
Ohadi et al. | Core promoter short tandem repeats as evolutionary switch codes for primate speciation | |
TNSN08252A1 (en) | Sirna anti myosine va et depigmentation de la peau | |
DE602005022443D1 (de) | Schnelle synthese von oligonukleotiden | |
MX2007004686A (es) | Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos. | |
JP2021520221A (ja) | 新規小分子活性化rna | |
WO2006045591A3 (en) | Method and constructs for delivering double stranded rna to pest organisms | |
BR0309766A (pt) | Promotores usp semente especìficos para expressar genes em vegetais | |
PE20212248A1 (es) | Molecula oligomerica de acido nucleico y uso de esta | |
WO2003104470A3 (en) | LET US RETURN FOR GENE TARGETING | |
WO2005042705A3 (en) | Short interfering rna and micro-rna compounds and methods of designing, making and using the same | |
MXPA02003422A (es) | Alteracion de la expresion de genes con adnss producido in vivo. | |
WO2009008645A3 (en) | Linear double-stranded rna molecule interfering with different target genes | |
WO2004094616A3 (en) | Silencing transcription by methylation | |
ATE491035T1 (de) | Verfahren zur abtrennung selektionierbarer markergensequenzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |